RESEARCH ARTICLE


Current and Emerging Therapeutic Regimens for Patients with Chronic Hepatitis C Infection



Pejman Solaimani1, Christopher Hogan2, 3, Matthew Chin2, 3, Juan L Miranda4, Douglas L Nguyen2, 3, *
1 Department of Medicine, University of California-Irvine, Irvine, CA, United States
2 Division of Gastroenterology and Hepatology, University of California-Irvine, Irvine, CA, United States
3 Division of Gastroenterology and Hepatology, VA Long Beach Health Care System, Irvine, CA, United States
4 Mental Health, Long Beach VA Medical Center, Irvine, CA, United States


Article Metrics

CrossRef Citations:
0
Total Statistics:

Full-Text HTML Views: 536
Abstract HTML Views: 304
PDF Downloads: 149
ePub Downloads: 99
Total Views/Downloads: 1088
Unique Statistics:

Full-Text HTML Views: 329
Abstract HTML Views: 183
PDF Downloads: 104
ePub Downloads: 79
Total Views/Downloads: 695



© Solaimani et al.; Licensee Bentham Open.

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/legalcode), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

* Address correspondence to this author at the Department of Medicine, UC Irvine School of Medicine, 333 City Blvd. West, Suite 400 Orange, CA 92868, USA; Tel: 714-456-6745; Fax: 714-456-7753; E-mail: douglaln@uci.edu


Abstract

With 5.2 million people living with Hepatitis C, it is the most common blood-borne infection in the United States. Untreated chronic HCV infection may result in adverse consequences such as cirrhosis, portal hypertension, hepatic failure and hepatocellular carcinoma. Previously approved treatments include Pegylated-interferon alpha-2a/2b plus ribavirin, Boceprevir and Telaprevir. Recently approved medications include Sofosbuvir (SOF), Simeprevir (SMV), Ledispavir-Sofosbuvir (Harvoni®) and Ombitasvir-paritaprevir-ritonavir with dasabuvir tablets (Viekira Pak). Here we review the literature describing the current and emerging therapies for chronic hepatitis C.

Keywords: Chronic, Direct acting antiviral agents, Hepatitis C, Treatment.